# Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer

> **NCT02810457** · PHASE3 · COMPLETED · sponsor: **Centus Biotherapeutics Limited** · enrollment: 731 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** FKB238 (bevacizumab)
- **DRUG:** Avastin (bevacizumab)
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT02810457
- **Lead sponsor:** Centus Biotherapeutics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-07
- **Primary completion:** 2019-01-24
- **Final completion:** 2022-01-26
- **Target enrollment:** 731 (ACTUAL)
- **Last updated:** 2022-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02810457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02810457, "Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02810457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*